Inozyme price target lowered to $12 from $24 at Raymond James

Raymond James analyst Ryan Deschner lowered the firm’s price target on Inozyme (INZY) to $12 from $24 and keeps an Outperform rating on the shares following the Q4 earnings report. Inozyme announced that it will implement cost-cutting measures in an effot to conserve capital and extend operational runway through the ENERGY 3 readout in 2026, the analyst tells investors in a research note. While Raymond James sees uncertainty associated with the anti-drug antibodies seen in infants in conjunction with the relatively abbreviated runway afforded by Inozyme’s current cash situation, the firm says these ADAs are a class effect in the enzyme replacement therapy space and could potentially resolve with higher dosing and/or a concomitant immunosuppression regimen, pediatric patients may not experience the same issues, and continuing treatment was recommended in all patients in ENERGY 1.